These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35007145)

  • 21. Osteonecrosis of the Jaw.
    Hamdy RC
    J Clin Densitom; 2017; 20(1):1-2. PubMed ID: 28259260
    [No Abstract]   [Full Text] [Related]  

  • 22. The biology of fracture healing in osteoporosis and in the presence of anti-osteoporotic drugs.
    Hak DJ
    Injury; 2018 Aug; 49(8):1461-1465. PubMed ID: 29709376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
    Brown JP; Morin S; Leslie W; Papaioannou A; Cheung AM; Davison KS; Goltzman D; Hanley DA; Hodsman A; Josse R; Jovaisas A; Juby A; Kaiser S; Karaplis A; Kendler D; Khan A; Ngui D; Olszynski W; Ste-Marie LG; Adachi J
    Can Fam Physician; 2014 Apr; 60(4):324-33. PubMed ID: 24733321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates and lower mortality risk: when it sounds to be good to be true ….
    Leslie WD
    Osteoporos Int; 2019 Dec; 30(12):2365-2367. PubMed ID: 31630216
    [No Abstract]   [Full Text] [Related]  

  • 25. Underdiagnosis and under-treatment of osteoporosis following fragility fracture.
    Aboyoussef M; Vierkoetter KR
    Hawaii Med J; 2007 Jul; 66(7):185-7. PubMed ID: 17879856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal Health Part 1: Overview Of Bone Health and Management In the Cancer Setting.
    Turner B; Ali S; Drudge-Coates L; Pati J; Nargund V; Wells P
    Urol Nurs; 2016; 36(1):17-21, 26. PubMed ID: 27093759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?
    Bischoff-Ferrari HA; Meyer O
    Ann Intern Med; 2014 Nov; 161(10):755-6. PubMed ID: 25199999
    [No Abstract]   [Full Text] [Related]  

  • 29. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures.
    Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV
    Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.
    ; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Pignone M; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2018 Jun; 319(24):2521-2531. PubMed ID: 29946735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
    Adler RA
    Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.
    Grover M; Bachrach LK
    Curr Osteoporos Rep; 2017 Aug; 15(4):271-282. PubMed ID: 28620868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on osteoporosis treatment.
    Nogués X; Martinez-Laguna D
    Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoporosis: What about men?
    Farford B; Balog J; Jackson KD; Montero D
    J Fam Pract; 2015 Sep; 64(9):542-52. PubMed ID: 26546951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
    Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
    Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.
    Crandall CJ; Newberry SJ; Diamant A; Lim YW; Gellad WF; Booth MJ; Motala A; Shekelle PG
    Ann Intern Med; 2014 Nov; 161(10):711-23. PubMed ID: 25199883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Absolute risk for fracture and WHO guideline. Pharmacological intervention to prevent osteoporotic fractures in the elderly].
    Hosoi T;
    Clin Calcium; 2007 Jul; 17(7):1098-104. PubMed ID: 17607078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis screening and risk management.
    Wilkins CH
    Clin Interv Aging; 2007; 2(3):389-94. PubMed ID: 18044189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.